feeling cold on semaglutide Why Am I Semaglutide? Causes and Remedies Is a Side Effect of

Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J

A recent perspective article highlighted that semaglutide demonstrated cardiovascular protective effects in individuals with obesity even before significant weight loss, suggesting that GLP-1 RAs may exert cardioprotection through weight-independent mechanisms 33

Autophagy impairment induces premature senescence in primary human fibroblasts

Cagrilintide takes yet another approach

Be patient with your progress and stay consistent with your dosing

What if my insurance does not cover treatment